Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jpeds.2021.06.012DOI Listing

Publication Analysis

Top Keywords

body mass
4
mass adjusted
4
adjusted pubertal
4
pubertal status
4
status metabolic
4
metabolic risk
4
body
1
adjusted
1
pubertal
1
status
1

Similar Publications

Background: The aim of this study was to establish a rat model of premature ovarian failure (POF) with cyclophosphamide (CTX), and explore the molecular basis of POF and the mechanism of Guishen-Erxian Decoction (GSEXD) to improve POF from the perspective of oxidative stress regulation of ovarian granulosa cell (OGC) DNA fragmentation.

Method: The study utilized SD rats to establish a POF model via CTX. Rats were divided into Control, POF group, three GSEXD dosage groups (low, medium, high), and a GSEXD+PI3K agonist group to assess GSEXD's therapeutic effects on oxidative stress, DNA fragmentation and ovarian damage.

View Article and Find Full Text PDF

The adverse effects of Western diets (WD), high in both fat and simple sugars, which contribute to obesity and related disorders, have been extensively studied in laboratory rodents, but not in non-laboratory animals, which limits the scope of conclusions. Unlike laboratory mice or rats, non-laboratory rodents that reduce body mass for winter do not become obese when fed a high-fat diet. However, it is not known whether these rodents are also resistant to the adverse effects of WD.

View Article and Find Full Text PDF

The purpose of this study was to evaluate the evolution of jump and sprint force-production capacities with maturation in young soccer players. One hundred sixteen young elite male soccer players aged 11-17 years were assigned to six different groups according to their maturity status. The force-velocity (F-V) profiles in jumping and sprinting performances were compared among groups.

View Article and Find Full Text PDF

[Tirzepatide (Mounjaro®) : a GIP/GLP-1 receptor dual agonist for the treatment of type 2 diabetes].

Rev Med Liege

September 2025

Service de Diabétologie, Nutrition et Maladies métaboliques, CHU Liège, Belgique.

Tirzepatide is a unimolecular dual agonist of both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, recently commercialized and reimbursed in Belgium for the treatment of type 2 diabetes (T2D). Because of the complementarity of action of the two incretins, tirzepatide showed, in a dose-dependent manner (5, 10 and 15 mg as a once-weekly subcutaneous injection), a better efficacy (greater reduction in HbA1c and body weight) compared with placebo, semaglutide 1 mg, basal insulin and preprandial boluses of insulin lispro in six studies of the SURPASS programme. Tirzepatide tolerance is almost similar to that of pure GLP-1 receptor agonists, with digestive adverse events, most often during the first weeks after initiation, which justifies the recommendation of progressive titration every four weeks.

View Article and Find Full Text PDF

[Focus on bariatric endoscopy in Belgium].

Rev Med Liege

September 2025

Service de Gastroentérologie, CHU Liège, Belgique.

Bariatric endoscopy is an increasingly recognized alternative to surgery for obesity treatment. Recent guidelines from leading medical societies (IFSO, ASMBS, ASGE, ESGE) have included endoscopic sleeve gastroplasty (ESG) and the intragastric balloon (IGB) in their recommendations. These procedures are indicated for patients with a body mass index (BMI) between 27 and 40 kg/m² who cannot or do not wish to undergo surgery.

View Article and Find Full Text PDF